High
5.620
Open
5.530
VWAP
5.47
Vol
979.95K
Mkt Cap
325.83M
Low
5.390
Amount
5.36M
EV/EBITDA(TTM)
--
Total Shares
59.41M
EV
256.26M
EV/OCF(TTM)
--
P/S(TTM)
--
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.168
-37.96%
--
--
-0.170
-32%
--
--
-0.188
-33.04%
Estimates Revision
The market is revising Upward the revenue expectations for Aldeyra Therapeutics, Inc. (ALDX) for FY2025, with the revenue forecasts being adjusted by 6.76% over the past three months. During the same period, the stock price has changed by 104.51%.
Revenue Estimates for FY2025
Revise Upward
+6.76%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-28.91%
In Past 3 Month
Stock Price
Go Up
+104.51%
In Past 3 Month
4 Analyst Rating
60.85% Upside
Wall Street analysts forecast ALDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALDX is 8.75 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
60.85% Upside
Current: 5.440
Low
6.00
Averages
8.75
High
10.00
60.85% Upside
Current: 5.440
Low
6.00
Averages
8.75
High
10.00
BTIG
Thomas Shrader
Strong Buy
Maintains
$11 → $9
2025-04-07
Reason
BTIG
Thomas Shrader
Price Target
$11 → $9
2025-04-07
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$10
2025-04-04
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$10
2025-04-04
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$10
2025-03-03
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$10
2025-03-03
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$10
2024-08-09
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$10
2024-08-09
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$10
2024-08-02
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$10
2024-08-02
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Aldeyra Therapeutics Inc (ALDX.O) is -14.50, compared to its 5-year average forward P/E of -8.18. For a more detailed relative valuation and DCF analysis to assess Aldeyra Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-8.18
Current PE
-14.50
Overvalued PE
-3.29
Undervalued PE
-13.08
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.94
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.67
Undervalued EV/EBITDA
-7.20
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
20.50
Current PS
8.12
Overvalued PS
60.20
Undervalued PS
-19.21
Financials
Annual
Quarterly
FY2025Q1
YoY :
+11.00%
-10.43M
Operating Profit
FY2025Q1
YoY :
+22.86%
-9.93M
Net Income after Tax
FY2025Q1
YoY :
+21.43%
-0.17
EPS - Diluted
FY2025Q1
YoY :
+25.04%
-12.47M
Free Cash Flow
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 3692.97% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
4.8M
USD
1
6-9
Months
0.0
USD
0
0-12
Months
127.3K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
4.4M
Volume
1
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
17.3K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 3692.97% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
4.8M
USD
1
6-9
Months
0.0
USD
0
0-12
Months
127.3K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ALDX News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
07:22:22
Aldeyra receives orphan designation for ADX-2191 from EMA
2025-07-17 (ET)
2025-07-17
07:04:23
Aldeyra announces FDA acceptance for review of reproxalap NDA
2025-06-26 (ET)
2025-06-26
07:06:44
Aldeyra receives special protocol assessment agreement letter from FDA
Sign Up For More Events
Sign Up For More Events
News
9.0
07-24NewsfilterPinnedAldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa
9.0
07-17NASDAQ.COMFDA Accepts Aldeyra's Resubmitted NDA For Reproxalap For Treatment Of Dry Eye Disease
9.0
07-17NASDAQ.COMAldeyra Therapeutics Says FDA Accepts Resubmitted NDA For Reproxalap To Treat Dry Eye Disease
Sign Up For More News
People Also Watch
DOMO
Domo Inc
16.130
USD
0.00%
RZLT
Rezolute Inc
5.870
USD
-0.17%
BRBS
Blue Ridge Bankshares Inc
3.810
USD
-3.54%
RGP
Resources Connection Inc
5.270
USD
-4.18%
AVIR
Atea Pharmaceuticals Inc
3.740
USD
+7.16%
DSGN
Design Therapeutics Inc
4.040
USD
-5.39%
AQST
Aquestive Therapeutics Inc
4.200
USD
-1.41%
ELMD
Electromed Inc
18.640
USD
-2.20%
FPH
Five Point Holdings LLC
6.430
USD
-0.46%
SMTI
Sanara Medtech Inc
25.650
USD
-6.32%
FAQ
What is Aldeyra Therapeutics Inc (ALDX) stock price today?
The current price of ALDX is 5.44 USD — it has decreased -1.63 % in the last trading day.
What is Aldeyra Therapeutics Inc (ALDX)'s business?
What is the price predicton of ALDX Stock?
What is Aldeyra Therapeutics Inc (ALDX)'s revenue for the last quarter?
What is Aldeyra Therapeutics Inc (ALDX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Aldeyra Therapeutics Inc (ALDX)'s fundamentals?
How many employees does Aldeyra Therapeutics Inc (ALDX). have?